艾迪药业(688488.SH)业绩快报：2025年净亏损1973.37万元

Core Insights - The company reported a total operating revenue of 721 million yuan for the fiscal year 2025, representing a year-on-year increase of 72.49% [1] - The company achieved an operating profit of 47.746 million yuan, marking a turnaround from loss to profit [1] - The total profit amounted to 24.3042 million yuan, also indicating a shift from loss to profit [1] - The net profit attributable to the parent company's owners was -19.7337 million yuan, with the loss margin decreasing by 86.02% compared to the previous year [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -20.9272 million yuan, with the loss margin decreasing by 85.90% year-on-year [1][2] Financial Performance - The company's total assets at the end of the reporting period were 1.916 billion yuan, an increase of 2.50% from the beginning of the period [1] - The equity attributable to the parent company's owners was 964 million yuan, a decrease of 1.67% from the beginning of the period [1] Key Drivers of Performance - The increase in revenue was primarily driven by higher income from innovative HIV drugs and the consolidation of Nanda Pharmaceutical's operational data, resulting in a gross profit increase of approximately 255 million yuan [2] - Sales expenses rose by approximately 92 million yuan due to increased efforts in new drug promotion and the consolidation of Nanda Pharmaceutical's operational data [2] - Asset impairment losses decreased by approximately 48 million yuan as market expansion and expectations stabilized [2]